The trial continues to enroll and follow participants
You should contact your GP or diabetes care team if you experience: Persistent difficulty remembering recent events or conversations Confusion or disorientation that is unusual for you Difficulty concentrating or completing familiar tasks Changes in mood, personality, or behaviour Memory problems that interfere with daily activities or work Your healthcare provider will conduct a thorough assessment to identify potential causes
All participants received treatment for at least 52 weeks, with a maximum treatment duration of 104 weeks or until the study was completed to collect and evaluate major adverse cardiovascular events (MACE)
For broader nutrition context on GLP-1s, see Diet and Weight Loss for how satiety signals change and why macronutrients matter
What They Are and Why Lifestyle Change Is Key to Sustained Weight Loss Mayo Clinic : Cleveland Clinic: Crohn's Disease Mount Sinai: GLP-1 Medications: Reimagining the Treatment Paradigm for Severe Crohns Disease Crohn's & Colitis Foundation: Key Insights from Crohns & Colitis Congress 2025: Revolutionary Research, Pregnancy Considerations, AI Innovations, and More Harvard Health Publishing: Do GLP-1 Drugs Reduce Inflammation
But its not clinical or roboticits surprisingly personal
